SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/100417"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/100417" > Letrozole therapy a...

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

Wallgren, Arne, 1940 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
Mouridsen, Henning (författare)
Giobbie-Hurder, Anita (författare)
visa fler...
Goldhirsch, Aron (författare)
Thürlimann, Beat (författare)
Paridaens, Robert (författare)
Smith, Ian (författare)
Mauriac, Louis (författare)
Forbes, John F (författare)
Price, Karen N (författare)
Regan, Meredith M (författare)
Gelber, Richard D (författare)
Coates, Alan S (författare)
visa färre...
 (creator_code:org_t)
 
visa fler...
 
visa färre...
2009
2009
Engelska.
Ingår i: The New England journal of medicine. - 1533-4406. ; 361:8, s. 766-76
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • BACKGROUND: The aromatase inhibitor letrozole, as compared with tamoxifen, improves disease-free survival among postmenopausal women with receptor-positive early breast cancer. It is unknown whether sequential treatment with tamoxifen and letrozole is superior to letrozole therapy alone. METHODS: In this randomized, phase 3, double-blind trial of the treatment of hormone-receptor-positive breast cancer in postmenopausal women, we randomly assigned women to receive 5 years of tamoxifen monotherapy, 5 years of letrozole monotherapy, or 2 years of treatment with one agent followed by 3 years of treatment with the other. We compared the sequential treatments with letrozole monotherapy among 6182 women and also report a protocol-specified updated analysis of letrozole versus tamoxifen monotherapy in 4922 women. RESULTS: At a median follow-up of 71 months after randomization, disease-free survival was not significantly improved with either sequential treatment as compared with letrozole alone (hazard ratio for tamoxifen followed by letrozole, 1.05; 99% confidence interval [CI], 0.84 to 1.32; hazard ratio for letrozole followed by tamoxifen, 0.96; 99% CI, 0.76 to 1.21). There were more early relapses among women who were assigned to tamoxifen followed by letrozole than among those who were assigned to letrozole alone. The updated analysis of monotherapy showed that there was a nonsignificant difference in overall survival between women assigned to treatment with letrozole and those assigned to treatment with tamoxifen (hazard ratio for letrozole, 0.87; 95% CI, 0.75 to 1.02; P=0.08). The rate of adverse events was as expected on the basis of previous reports of letrozole and tamoxifen therapy. CONCLUSIONS: Among postmenopausal women with endocrine-responsive breast cancer, sequential treatment with letrozole and tamoxifen, as compared with letrozole monotherapy, did not improve disease-free survival. The difference in overall survival with letrozole monotherapy and tamoxifen monotherapy was not statistically significant. (ClinicalTrials.gov number, NCT00004205.)

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

Antineoplastic Agents
Hormonal
administration & dosage
adverse effects
Aromatase Inhibitors
administration & dosage
adverse effects
Breast Neoplasms
drug therapy
Chemotherapy
Adjuvant
Disease-Free Survival
Double-Blind Method
Drug Administration Schedule
Female
Follow-Up Studies
Fractures
Bone
epidemiology
Humans
Incidence
Kaplan-Meiers Estimate
Neoplasm Recurrence
Local
prevention & control
Nitriles
administration & dosage
adverse effects
Postmenopause
Proportional Hazards Models
Tamoxifen
administration & dosage
adverse effects
Triazoles
administration & dosage
adverse effects

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy